Curcuminoid-inspired synthetic compounds as anti-tumor agents
Novel CUR— and CUR—BF2 compounds as well as novel bis and mono-NSAID/CUR—BF2 and NSAID/CUR hybrids exhibiting anti-tumor properties are presented. CUR compounds bearing fluorinated moieties with selective fluorine introduction into the α-carbonyl moiety as well as CUR—BF2 adducts and CURs with diverse substitution patterns in the phenyl rings including fluorinated substituents (SCF3, OCF3, and F) and/or bulky activating groups (OMe, OAc, and OBz) are presented. Fluorinated aryl-pyrazoles and isoxazoles as well as novel CUR and CUR—BF2 compounds with monocyclic aromatic and bicyclic-heteroaromatic lateral rings, bearing fluorine(s), OCF3, CF3, and SCF3 groups, and their alpha-carbonyl-fluorinated analogs, as well as their pyrazole and isoxazole derivatives are presented. The CUR-pyrazoles embody analogs that are fluorinated at the phenyl-pyrazole moiety. The hybrids, compounds, and their derivatives exhibited exceptional cytotoxic and anti-proliferative activity against several cancer cell-lines. The hybrid NSAID/CUR compounds also exhibited exceptional anti-inflammatory activity over NSAID or curcumin alone..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Europäisches Patentamt - (2021) vom: 14. Sept. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
LAALI KENNETH K [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-09-14, Last update posted on www.tib.eu: 2022-09-09, Last updated: 2023-02-09 |
---|
Patentnummer: |
US11117907 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA013505513 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA013505513 | ||
003 | DE-627 | ||
005 | 20230504080623.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230215s2021 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA013505513 | ||
035 | |a (EPA)US11117907 | ||
035 | |a (EPA)74881719 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a LAALI KENNETH K |e verfasserin |4 aut | |
245 | 1 | 0 | |a Curcuminoid-inspired synthetic compounds as anti-tumor agents |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2021-09-14, Last update posted on www.tib.eu: 2022-09-09, Last updated: 2023-02-09 | ||
520 | |a Novel CUR— and CUR—BF2 compounds as well as novel bis and mono-NSAID/CUR—BF2 and NSAID/CUR hybrids exhibiting anti-tumor properties are presented. CUR compounds bearing fluorinated moieties with selective fluorine introduction into the α-carbonyl moiety as well as CUR—BF2 adducts and CURs with diverse substitution patterns in the phenyl rings including fluorinated substituents (SCF3, OCF3, and F) and/or bulky activating groups (OMe, OAc, and OBz) are presented. Fluorinated aryl-pyrazoles and isoxazoles as well as novel CUR and CUR—BF2 compounds with monocyclic aromatic and bicyclic-heteroaromatic lateral rings, bearing fluorine(s), OCF3, CF3, and SCF3 groups, and their alpha-carbonyl-fluorinated analogs, as well as their pyrazole and isoxazole derivatives are presented. The CUR-pyrazoles embody analogs that are fluorinated at the phenyl-pyrazole moiety. The hybrids, compounds, and their derivatives exhibited exceptional cytotoxic and anti-proliferative activity against several cancer cell-lines. The hybrid NSAID/CUR compounds also exhibited exceptional anti-inflammatory activity over NSAID or curcumin alone. | ||
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
650 | 4 | |a che | |
650 | 4 | |a C07C: Acyclic or carbocyclic compounds (macromolecular compounds c08;production of organic compounds by electrolysis or electrophoresis c25b0003000000, c25b0007000000) | |
650 | 4 | |a C07F: Acyclic, carbocyclic, or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium (metal-containing porphyrins c07d0487220000;macromolecular compounds c08) | |
650 | 4 | |a 615 | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 14. Sept. |
773 | 1 | 8 | |g year:2021 |g day:14 |g month:09 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/74881719/publication/US11117907A1?q=US11117907 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
912 | |a SSG-OLC-PHA | ||
936 | u | w | |j 2021 |b 14 |c 09 |
951 | |a AR | ||
952 | |j 2021 |b 14 |c 09 |